<p>RNA sequencing (RNA-Seq) was performed on 94 multiple myeloma (MM) patient samples. We used genomic subgroup and high-risk markers to identify therapeutic targets, including <a href="https://www.ncbi.nlm.nih.gov/gene/608">TNFRSF17</a>, <a href="https://www.ncbi.nlm.nih.gov/gene/55507">GPRC5D</a>, <a href="https://www.ncbi.nlm.nih.gov/gene/3676">ITGA4</a>, and <a href="https://www.ncbi.nlm.nih.gov/gene/54900">LAX1</a>, with low predicted toxicity and high specificity to MM and genomic subgroups such as those with <a href="https://www.ncbi.nlm.nih.gov/gene/7157">TP53</a> alterations.</p>

Identification of Novel Immunotherapy Targets in Myeloma

Multiple Myeloma study with RNA-Seq data on dbGaP (89 participants)